Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Dr. Mesa on Rechallenging With JAK Inhibitor Therapy in MPNs

July 23rd 2020

Ruben A. Mesa, MD, discusses the potential clinical benefit of rechallenging with JAK inhibitor therapy in patients with myeloproliferative neoplasms.

CCC-19 Registry Data Show Increased COVID-19–Associated Mortality in Patients With Cancer

July 22nd 2020

The mortality rate with COVID-19 appears to be higher in patients with cancer—especially those with lung cancer—compared with the general population, and several factors associated with mortality are beginning to emerge.

Fate Therapeutics Receives FDA Clearance of IND for FT819 in B-Cell Malignancies

July 22nd 2020

The FDA has cleared an investigational new drug application for the first-of-its-kind, off-the-shelf CAR T-cell product FT819, which targets CD19-positive malignancies.

FDA Sets Review Date for Remestemcel-L for Steroid-Refractory Pediatric Acute GVHD

July 21st 2020

The FDA’s Oncologic Drugs Advisory Committee has scheduled a date to review data supporting the biologics license application for remestemcel-L as a treatment for children with steroid-refractory acute graft versus host disease.

Dr. Komrokji on the Current Treatment Landscape in MDS

July 21st 2020

Rami Komrokji, MD, discusses the current treatment landscape in myelodysplastic syndrome.

Dr. Shaughnessy on the Emergence of CAR T-Cell Therapy in Hematologic Malignancies

July 21st 2020

Paul J. Shaughnessy, MD, discusses the emergence of CAR T-cell therapy in hematologic malignancies.

Dr. Burke on Current FDA Indications for BTK Inhibitors in B-Cell Malignancies

July 20th 2020

John M. Burke, MD, discusses current indications for BTK inhibitors in B-cell malignancies.

FDA Approval Sought for Selinexor in Myeloma After 1 Prior Line of Therapy

July 20th 2020

The FDA has accepted a supplemental new drug application seeking approval for selinexor for the treatment of patients with multiple myeloma following at least 1 previous line of therapy.

Progress in the Treatment of AML

July 20th 2020

Implications for Treating AML With CC-486

July 20th 2020

CC-486 Maintenance Therapy in AML

July 20th 2020

Gemtuzumab for AML

July 20th 2020

CPX-351 in Newly Diagnosed Secondary AML

July 20th 2020

Differentiation Syndrome and IDH Inhibitors in AML

July 20th 2020

IDH Inhibitors and MDS

July 20th 2020

IDH1/2 Inhibitors for AML

July 20th 2020

IDH Mutations in AML

July 20th 2020

FLT3 Triplet Regimens for AML

July 20th 2020

Monitoring Response to Venetoclax Regimens in AML

July 20th 2020

Venetoclax in AML: Safety Profile

July 20th 2020